Earnings call transcript: Yatsen Q2 2025 sees revenue surge, stock gains

Yatsen Holding (YSG) reported robust Q2 2025 financial results, with total net revenues surging 36.8% year-over-year to 1.09 billion RMB and gross margin improving to 78.3%. The company achieved a non-GAAP net profit margin of 1.1% and significantly narrowed its net loss margin to 1.8%, driven primarily by an 88.1% increase in skincare brand revenues and strategic investments in R&D and retail expansion. Following the announcement, YSG's stock rose 2.73% in premarket trading, with the company forecasting Q3 2025 revenue growth of 15% to 30% amidst a competitive market landscape.

Analysis

Yatsen Holding demonstrated a significant operational turnaround and robust growth in its Q2 2025 results, substantially outperforming a sluggish Chinese beauty market that grew only 2.6%. The company's total net revenues surged 36.8% year-over-year to 1.09 billion RMB, driven by an exceptional 88.1% growth in its skincare division, indicating its strategic pivot towards higher-margin products is proving effective. This shift also contributed to an improved gross margin of 78.3%, up from 76.7% in the prior year. Critically, Yatsen achieved non-GAAP profitability for the third consecutive quarter with a 1.1% margin and dramatically narrowed its net loss margin to 1.8% from 10.8%, showcasing increased operating leverage as expenses as a percentage of revenue declined. Management’s confident forward guidance, projecting 15% to 30% revenue growth for Q3, and the stock's powerful price momentum, with a 166.48% return over the past year, signal that its R&D-focused strategy is yielding tangible results and gaining market validation.

Key Decisions for Investors

• The strong top-line beat, margin expansion, and sustained non-GAAP profitability validate the company's R&D-driven turnaround strategy, suggesting investors may view these results as a strong positive catalyst.
• Investors should closely monitor the skincare segment's growth trajectory and the market reception of new products, as these are the primary drivers of the company's current outperformance and future success.
• Given the stock's negative beta of -2.11, it may serve as a potential portfolio diversifier, offering performance that is counter-cyclical to broader market trends, though competitive and macroeconomic risks in China remain a key consideration.